Is it Wise to Invest in Roche Holding (RHHBY)?

Harding Loevner, an investment management firm, published its “International Equity ADR Fund” fourth-quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly net return of 4.28% was recorded by the fund for the fourth quarter of 2021, beating its Benchmarks, the MSC All Country World ex-US Index, and the MSCI EAFE Index, which returned 1.88% and 2.74% respectively for the same period. Spare some time to check the fund’s top 5 holdings to have a clue about their top bets for 2022.

Harding Loevner International Equity ADR Fund, in its Q4 2021 investor letter, mentioned Roche Holding AG (NYSE: RHHBY) and discussed its stance on the firm. Roche Holding AG is a Basel, Switzerland-based multinational healthcare company with a $328.2 billion market capitalization. RHHBY delivered a -9.03% return since the beginning of the year, while its 12-month returns are up by 16.10%. The stock closed at $47.02 per share on March 02, 2022.

Here is what Harding Loevner International Equity ADR Fund has to say about Roche Holding AG in its Q4 2021 investor letter:

“Health Care boosted relative performance as our holdings benefitted from the pandemic both coming and going. Roche and Lonza saw heightened interest in treatment, testing, and vaccination activities to battle the waves of newer COVID-19 variants.

Source: Unsplash

Our calculations show that Roche Holding AG (NYSE: RHHBY) failed to obtain a mark on our list of the 30 Most Popular Stocks Among Hedge Funds. RHHBY was in 3 hedge fund portfolios at the end of the fourth quarter of 2021, compared to 3 funds in the previous quarter. Roche Holding AG (NYSE: RHHBY) delivered a -5.04% return in the past 3 months.

In December 2021, we also shared another hedge fund’s views on RHHBY in another article. You can find other letters from hedge funds and prominent investors on our hedge fund investor letters 2021 Q4 page.

Disclosure: None. This article is originally published at Insider Monkey.